The total return over the past 12 months is +155.31% vs. +16.94% for the S&P 500. So far it's up +30.00% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +155.31% | +10.69% | (33.98%) | N/A | N/A | N/A |
| Total Return CAGR | +155.31% | +10.69% | (33.98%) | N/A | N/A | N/A |
| Revenue CAGR | +220.34% | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Prelude Therapeutics Incorporated (PRLD)
| Year | Start price | End price | PRLD Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.90 | $3.77 | +30.00% | +14.51% | +15.49% |
| 2025 | $1.27 | $2.90 | +128.35% | +17.72% | +110.63% |
| 2024 | $4.27 | $1.27 | (70.26%) | +24.89% | (95.15%) |
| 2023 | $6.04 | $4.27 | (29.30%) | +26.19% | (55.49%) |
| 2022 | $12.45 | $6.04 | (51.49%) | (18.17%) | (33.32%) |
| 2021 | $71.55 | $12.45 | (82.60%) | +28.74% | (111.34%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
